An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy

Current Opinion in Hematology

Volumn 10, Issue 2, 2003, Pages 99-107

  Reiter, Christopher D ^b   Gladwin, Mark T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ESTROGEN; HEMOGLOBIN; HEMOGLOBIN F; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN; SUPEROXIDE; VASCULAR CELL ADHESION MOLECULE 1;

BIOAVAILABILITY; BLOOD VESSEL OCCLUSION; CELL DENSITY; ENZYME ACTIVITY; ERYTHROCYTE; GAS ANALYSIS; GENDER; HEMODYNAMICS; HOMEOSTASIS; HUMAN; INFLAMMATION; LUNG ARTERY PRESSURE; LUNG VENTILATION; NONHUMAN; OXYGEN AFFINITY; PATHOPHYSIOLOGY; PERFUSION; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVIEW; SEX DIFFERENCE; SICKLE CELL ANEMIA; TRANSGENIC MOUSE;

ANEMIA, SICKLE CELL; ANIMALS; ENDOTHELIUM, VASCULAR; HEMOGLOBINS; HOMEOSTASIS; HUMANS; NITRIC OXIDE;

EID: 0037372314     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200303000-00001     Document Type: Review

References (111)

1. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylchotine. Nature 1980, 288:373-376.
2. Ignarro LJ, Byrns RE, Buga GM, et al.: Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987, 61:866-879.
3. Ignarro LJ, Buga GM, Wood KS, et al.: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987, 84:9265-9269.
4. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
5. Palmer RM, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988, 333:664-666.
6. Panza JA, Casino PR, Kilcoyne CM, et al.: Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993, 87:1468-1474.
7. Ludmer PL, Selwyn AP, Shook TL, et al.: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046-1051.
8. Quyyumi AA, Dakak N, Andrews NP, et al.: Nitric oxide activity in the human coronary circulation: impact of risk factors for coronary atherosclerosis. J Clin Invest 1995, 95:1747-1755.
9. Belcher JD, Marker PH, Weber JP, et al.: Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vasoocclusion. Blood 2000, 96:2451-2459.
10. Kaul DK, Hebbel RP: Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 2000, 106:411-420. •• This study demonstrated increased inflammation (increased adherent and extravasated leukocytes mediated through P-selectin) after hypoxia plus reoxygenation in transgenic sickle cell mice, consistent with ischemia-reperfusion pathophysiology in vaso-occlusive crisis.
11. Osarogiagbon UR, Choong S, Belcher JD, et al.: Reperfusion injury pathophysiology in sickle transgenic mice. Blood 2000, 96:314-320.
12. Diwan BA, Gladwin MT, Noguchi CT, et al.: Renal pathology in hemizygous sickle cell mice. Toxicol Pathol 2002, 30:254-262.
13. Noguchi CT, Gladwin M, Diwan B, et al.: Pathophysiology of a sickle cell trait mouse model: human alpha(beta)(S) transgenes with one mouse beta-globin allele. Blood Cells Mol Dis 2001, 27:971-977.
14. Kaul DK, Liu XD, Fabry ME, et al.: Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am J Physiol Heart Circ Physiol 2000, 278:H1799-H1806.
15. Nath KA, Shah V, Haggard JJ, et al.: Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1949-R1955.
16. Asian M, Ryan TM, Adler B, et al.: Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001, 98:15215-15220. •• This study shows that levels of superoxide-generating xanthine oxidase on the lumenal surface of the vasculature are elevated in transgenic sickle cell mice and in the plasma of patients with sickle cell disease. Because superoxide reacts with and inactivates NO at diffusion-limited rates, their observation may explain the endothelial dysfunction observed in these mice. They showed that a superoxide scavenger rescues vasoresponse.
17. Punzalan RC, Holzman S, Trost BA et al.: Spontaneous stroke and increased erythrocyte adhesion in transgenic knockout sickle cell mice. Blood 1999, 94:419A.
18. Rees DC, Cervi P, Grimwade D, et al.: The metabolites of nitric oxide in sickle-cell disease. Br J Haematol 1995, 91:834-837.
19. Morris CR, Kuypers FA, Larkin S, et al.: Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol 2000, 111:498-500.
20. Morris CR, Kuypers FA, Larkin S, et al.: Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000, 22:515-520.
21. -) vary inversely with plasma soluble VCAM-1 levels in patients with sickle cell disease with acute chest syndrome, suggesting that reduced NO bioavailability contributes to the acute chest syndrome.
22. Enwonwu CO, Xu XX, Turner E: Nitrogen metabolism in sickle cell anemia: free amino acids in plasma and urine. Am J Med Sci 1990, 300:366-371.
23. Gladwin MT, Schechter AN, Ognibene FP et al.: Divergent nitric oxide bioavailability in men and women with sickle cell anemia. Circulation 2002, in press. •• See [24•].
24. Belhassen L, Pelle G, Sediame S, et al.: Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001, 97:1584-1589. • These two studies [23••,24•] are complementary and consistent and show an increased response of forearm blood flow in patients with sickle cell disease to infusions of acetylcholine; however, Gladwin et al. [23••] show that these responses are different between males and females. In male patients with sickle cell disease, NO-dependent vasodilation was blunted.
25. Walker HA, Dean TS, Sanders TA, et al.: The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17ss-estradiol. Circulation 2001, 103:258-262.
26. Koh KK, Blum A, Hathaway L, et al.: Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation 1999, 100:1851-1857.
27. Guetta V, Quyyumi AA, Prasad A, et al.: The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997, 96:2795-2801.
28. Hayashi T, Yamada K, Esaki T, et al.: Effect of estrogen on isoforms of nitric oxide synthase: possible mechanism of anti-atherosclerotic effect of estrogen. Gerontology 1997, 43:24-34.
29. Hayashi T, Fukuto JM, Ignarro LJ, et al.: Gender differences in atherosclerosis: possible role of nitric oxide. J Cardiovasc Pharmacol 1995, 26:792-802.
30. Hayashi T, Fukuto JM, Ignarro LJ, et al.: Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A 1992, 89:11259-11263.
31. Weiner CP, Lizasoain I, Baylin SA, et al.: Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A 1994, 91:5212-5216.
32. Chowienczyk PJ, Watts GF, Cockcroft JR, et al.: Sex differences in endothelial function in normal and hypercholesterolaemic subjects. Lancet 1994, 344:305-306.
33. Gilligan DM, Badar DM, Panza JA, et al.: Acute vascular effects of estrogen in postmenopausal women. Circulation 1994, 90:786-791.
34. Sack MN, Rader DJ, Cannon RO III: Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994, 343:269-270.
35. Platt OS, Brambilla DJ, Rosse WF, et al.: Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994, 330:1639-1644.
36. Baum KF, Dunn DT, Maude GH, et al.: The painful crisis of homozygous sickle cell disease: a study of the risk factors. Arch Intern Med 1987, 147:1231-1234.
37. Platt OS, Thorington BD, Brambilla DJ, et al.: Pain in sickle cell disease: rates and risk factors. N Engl J Med 1991, 325:11-16.
38. Chang YC, Smith KD, Moore RD, et al.: An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, beta-globin haplotypes, alpha-globin gene number, gender, and age. Blood 1995, 85:1111-1117.
39. Dover GJ, Smith KD, Chang YC, et al.: Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 1992, 80:816-824.
40. Steinberg MH, Hsu H, Nagel RL, et al.: Gender and haplotype effects upon hematological manifestations of adult sickle cell anemia. Am J Hematol 1995, 48:175-181.
41. Ikuta T, Ausenda S, Cappellini MD: Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci U S A 2001, 98:1847-1852. •• The NO-soluble guanylyl cyclase-cyclic GMP-MAP kinase pathway in the human erythroleukemic cell line K562 mediates fetal hemoglobin induction by butyrate.
42. Cokic VP, Smith RD, Beleslin-Cokic BB, et al.: Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2002, in press.
43. Fabry ME, Witt WM, Suzuka SM: Impact of HbF and gender on mean survival time of NY1KO sickle transgenic mice expressing exclusively human hemoglobins [abstract]. Blood 2001, 98:750a.
44. Reiter CD, Wang X, Tanus-Santos JE, et al.: Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med 2002, 8:1383-1389. •• This investigation demonstrates that chronic intravascular hemolysis, leading to elevated levels of cell-free hemoglobin, eliminates NO bioavailability. Inhaled NO as a therapy inactivates cell-free hemoglobin in the pulmonary vasculature, which increases NO bioavailability in the periphery.
45. Carlsen E, Comroe JH: The rate of uptake of carbon monoxide and of nitric oxide by normal human erythrocytes and experimentally produced spherocytes. J Gen Physiol 1958, 42:83-107.
46. Liu X, Miller MJ, Joshi MS, et al.: Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem 1998, 273:18709-18713.
47. Lancaster JR Jr: A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide 1997, 1:18-30.
48. Vaughn MW, Kuo L, Liao JC: Effective diffusion distance of nitric oxide in the microcirculation. Am J Physiol 1998, 274:H1705-H1714.
49. Vaughn MW, Huang KT, Kuo L, et al.: Erythrocytes possess an intrinsic barrier to nitric oxide consumption. J Biol Chem 2000, 275:2342-2348.
50. Huang KT, Han TH, Hyduke DR, et al.: Modulation of nitric oxide bioavailability by erythrocytes. Proc Natl Acad Sci U S A 2001, 98:11771-11776.
51. Coin JT, Olson JS: The rate of oxygen uptake by human red blood cells. J Biol Chem 1979, 254:1178-1190.
52. Butler AR, Megson IL, Wright PG: Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim Biophys Acta 1998, 1425:168-176.
53. Liao JC, Hein TW, Vaughn MW, et al.: Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc Natl Acad Sci U S A 1999, 96:8757-8761.
54. Pohl U, Lamontagne D: Impaired tissue perfusion after inhibition of endothelium-derived nitric oxide. Basic Res Cardiol 1991, 86:97-105.
55. Hess JR, MacDonald VW, Brinkley WW: Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Physiol 1993, 74:1769-1778.
56. Lee R, Neya K, Svizzero TA, et al.: Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J Appl Physiol 1995, 79:236-242.
57. de Figueiredo LF, Mathru M, Solanki D, et al.: Pulmonary hypertension and systemic vasoconstriction may offset the benefits of acellular hemoglobin blood substitutes. J Trauma 1997, 42:847-856.
58. Vogel WM, Dennis RC, Cassidy G, et al.: Coronary constrictor effect of stroma-free hemoglobin solutions. Am J Physiol 1986, 251:H413-H420.
59. Ulatowski JA, Nishikawa T, Matheson-Urbaitis B, et al.: Regional blood flow alterations after bovine fumaryl beta beta-crosslinked hemoglobin transfusion and nitric oxide synthase inhibition. Crit Care Med 1996, 24:558-565.
60. Murray JA, Ledlow A, Launspach J, et al.: The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology 1995, 109:1241-1248.
61. Sloan EP, Koenigsberg M, Gens D, et al.: Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999, 282:1857-1864.
62. Crosby WH: The metabolism of hemoglobin and bile pigment in hemolytic disease. Am J Med 1955, 18:112-122.
63. Naumann HN, Diggs LW, Barreras L, et al.: Plasma hemoglobin and hemoglobin fractions in sickle cell crisis. Am J Clin Pathol 1971, 56:137-147.
64. Sprinkle RH, Cole T, Smith S, et al.: Acute chest syndrome in children with sickle cell disease: a retrospective analysis of 100 hospitalized cases. Am J Pediatr Hematol Oncol 1986, 8:105-110.
65. Bevilacqua MP, Pober JS, Mendrick DL, et al.: Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci U S A 1987, 84:9238-9242.
66. Springer TA: Adhesion receptors of the immune system. Nature 1990, 346:425-434.
67. Cybulsky MI, Gimbrone MA Jr: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251:788-791.
68. Cybulsky MI, Iiyama K, Li H, et al.: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001, 107:1255-1262.
69. Gee BE, Platt OS: Sickle reticulocytes adhere to VCAM-1. Blood 1995, 85:268-274.
70. Swerlick RA, Eckman JR, Kumar A, et al.: Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood 1993, 82:1891-1899.
71. Natarajan M, Udden MM, McIntire LV: Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro. Blood 1996, 87:4845-4852.
72. Setty BN, Stuart MJ: Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood 1996, 88:2311-2320.
73. Duits AJ, Pieters RC, Saleh AW, et al.: Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol 1996, 81:96-98.
74. Shiu YT, Udden MM, McIntire LV: Perfusion with sickle erythrocytes upregulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 2000, 95:3232-3241.
75. Gladwin MT, Shelhamer JH, Ognibene FP, et al.: Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002, 116:436-444.
76. De Caterina R, Libby P, Peng HB, et al.: Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995, 96:60-68.
77. Setty BN, Stuart MJ: Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood 1996, 88:2311-2320.
78. Atz AM, Wessel DL: Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology 1997, 87:988-990.
79. Sullivan KJ, Goodwin SR, Evangelist J, et al.: Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med 1999, 27:2563-2568.
80. Sutton LL, Castro O, Cross DJ, et al.: Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994, 74:626-628.
81. Minter KR, Gladwin MT: Pulmonary complications of sickle cell anemia: a need for increased recognition, treatment, and research. Am J Respir Crit Care Med 2001, 164:2016-2019.
82. Ghofrani HA, Wiedemann R, Rose F, et al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360:895-900. •• This study demonstrates that the oral phosphodiesterase 5 inhibitor, sildenafil (Viagra; Pfizer US Pharmaceutical Group, New York, NY), is a selective pulmonary vasodilator, reducing pulmonary artery pressures and increasing oxygenation in patients with pulmonary hypertension secondary to lung fibrosis. Similar effects could be anticipated in patients with secondary pulmonary hypertension secondary to sickle cell disease.
83. Lepore J, Maroo A, Pereira NL, et al.: Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002, 90:677.
84. Castro OL, Hoque M, Brown BD: Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2002, 3:3. •• Report on pulmonary pressures from right heart catheterization in patients with sickle cell anemia. This study reveals a 2-year median survival in patients with secondary pulmonary hypertension.
85. Littera R, La Nasa G, Derchi G, et al.: Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood 2002, 100:1516-1517.
86. Dellinger RP, Zimmerman JL, Taylor RW, et al.: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998, 26:15-23.
87. Guidot DM, Hybertson BM, Kitlowski RP, et al.: Inhaled NO prevents IL-1-induced neutrophil accumulation and associated acute edema in isolated rat lungs. Am J Physiol 1996, 271:L225-L229.
88. Bloomfield GL, Holloway S, Ridings PC, et al.: Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury. Crit Care Med 1997, 25:584-593.
89. Fox-Robichaud A, Payne D, Hasan SU, et al.: Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest 1998, 101:2497-2505.
90. Cannon RO III, Sehechter AN, Panza JA, et al.: Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest 2001, 108:279-287. •• This study has shown the surprising result that inhaled NO, or an inhaled NO metabolite, can systemically vasodilate during regional NO synthase blockade or during exercise.
91. Schechter AN, Gladwin MT, Cannon RO III: NO solutions? J Clin Invest 2002, 109:1149-1151.
92. Romero JR, Suzuka SM, Nagel RL, et al.: Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood 2002, 99:1103-1108. •• Dietary supplementation with arginine for up to 11 months reduces red blood cell density in a transgenic sickle cell mouse model.
93. De Franceshi L, Baron A, Scarpa A, et al.: Inhaled nitric oxide has a protective effect in hypoxic transgenic sickle cell mice (SAD): evidences of modulation of ischemic lung injury. Blood 2001 (suppl):3125.
94. Head CA, Brugnara C, Martinez-Ruiz R, et al.: Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest 1997, 100:1193-1198.
95. Martinez-Ruiz R, Montero-Huerta P, Hriomi J, et al.: Inhaled nitric oxide improves survival rates during hypoxia in a sickle cell (SAD) mouse model. Anesthesiology 2001, 94:1113-1118.
96. Schechter AN: NO therapy? [editorial]. J Clin Invest 1997, 100:955-956.
97. Hrinczenko BW, Alayash AI, Wink DA, et al.: Effect of nitric oxide and nitric oxide donors on red blood cell oxygen transport. Br J Haematol 2000, 110:412-419.
98. Gladwin MT, Schechter AN, Shelhamer JH, et al.: Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest 1999, 104:937-945.
99. Gladwin MT, Ognibene FP, Shelhamer JH, et al.: Nitric oxide transport on sickle cell hemoglobin: where does it bind? Free Radic Res 2001, 35:175-180.
100. Xu X, Lockamy VL, Chen K, et al.: Effects of iron nitrosylation on sickle cell hemoglobin solubility. J Biol Chem 2002, 277:36787-36792. • This study demonstrated that NO-heme ligation of hemoglobin S has minimal effects on polymerization, requiring substantial modification for effect.
101. Bonaventura C, Ferruzzi G, Tesh S, et al.: Effects of S-nitrosation on oxygen binding by normal and sickle cell hemoglobin. J Biol Chem 1999, 274:24742-24748.
102. Garel MC, Domenget C, Galacteros F, et al.: Inhibition of erythrocyte sickling by thiol reagents. Mol Pharmacol 1984, 26:559-565.
103. Garel MC, Domenget C, Caburi-Martin J, et al.: Covalent binding of glutathione to hemoglobin, I: inhibition of hemoglobin S polymerization. J Biol Chem 1986, 261:14704-14709.
104. Gladwin MT, Ognibene FP, Pannell LK, et al.: Relative role of heme nitrosylation and beta-cysteine 93 nitrosation in the transport and metabolism of nitric oxide by hemoglobin in the human circulation. Proc Natl Acad Sci U S A 2000, 97:9943-9948.
105. Charache S, Terrin ML, Moore RD, et al.: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia: Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995, 332:1317-1322.
106. Pacelli R, Taira J, Cook JA, et al.: Hydroxyurea reacts with heme proteins to generate nitric oxide [letter]. Lancet 1996, 347:900.
107. Kim-Shapiro DB, King SB, Bonifant CL, et al.: Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin. Biochim Biophys Acta 1998, 1380:64-74.
108. Kim-Shapiro DB, King SB, Shields H, et al.: The reaction of deoxy-sickle cell hemoglobin with hydroxyurea. Biochim Biophys Acta 1999, 1428:381-387.
109. Rupon JW, Domingo SR, Smith SV, et al.: The reactions of myoglobin, normal adult hemoglobin, sickle cell hemoglobin and hemin with hydroxyurea. Biophys Chem 2000, 84:1-11.
110. Glover RE, Ivy ED, Orringer EP, et al.: Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol 1999, 55:1006-1010.
111. Nahavandi M, Wycke MQ, Perlin E, et al.: Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea; hemoglobinopathy. Hematology 2000, 5:335-339.